In the field of hemophilia non-antibody and antibody treatment, Takeda Korea Pharmaceutical and JW Pharmaceutical are gaining attention as they are strengthening their positions.

Korea Takeda Pharmaceutical's 'Advate/Adynovate', and JW Pharmaceutical's Hemlibra's sales last year were 26.2 billion won and 7.6 billion won, respectively, ranking first in related markets. Of particular note is that the hemophilia antibody treatment market is fluctuating in line with the launch of Hemlibra in 2020. Due to the emergence of strong competing products, the external expansion of traditional powerhouses Novoseven RT and Faiva is drawing a steep downward curve.

Novoseven RT·Faiva's sales from 2018